Cited by 127Dementia and Cognitive Impairment ResearchNeurological Disease Mechanisms and TreatmentsCerebrovascular and genetic disorders

Cerebrovascular disease, beta-amyloid, and cognition in aging

Open access
Marchant, Natalie L., Reed, Bruce R., DeCarli, Charles S., Madison, Cindee M., Weiner, Michael W., Chui, Helena C., Jagust, William J.·2012·Neurobiology of Aging

Abstract

The present study evaluated cerebrovascular disease (CVD), β-amyloid (Aβ), and cognition in clinically normal elderly adults. Fifty-four participants underwent magnetic resonance imaging (MRI), Pittsburgh compound B (PIB)-positron emission tomography (PET) imaging, and neuropsychological evaluation. High white matter hyperintensity burden and/or presence of infarct defined CVD status (CVD-: n = 27; CVD+: n = 27). PIB-positron emission tomography ratios of Aβ deposition were extracted using Logan plotting (cerebellar reference). Presence of high levels of Aβ in prespecified regions determined PIB status (PIB-: n = 33; PIB+: n = 21). Executive functioning and episodic memory were measured using composite scales. CVD and Aβ, defined as dichotomous or continuous variables, were unrelated to one another. CVD+ participants showed lower executive functioning (p = 0.001) when compared with CVD- individuals. Neither PIB status nor amount of Aβ affected cognition (ps ≥ 0.45), and there was no statistical interaction between CVD and PIB on either cognitive measure. Within this spectrum of normal aging CVD and Aβ aggregation appear to be independent processes with CVD primarily affecting cognition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2011.10.001

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Aβ plaques may be found in 35% of cognitively healthy individuals above the age of 60.

    “the Aβ plaques may be found in 35% of cognitively healthy individuals above the age of 60 [290]”

    From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [290]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 86 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Marchant, N. L., Reed, B. R., DeCarli, C. S., Madison, C. M., Weiner, M. W., Chui, H. C., & Jagust, W. J.
Affiliations
  • Lawrence Berkeley National Laboratory (US)
  • University of California, Davis (US)
  • University of California, Berkeley (US)
  • University of California, San Francisco (US)
  • University of Southern California (US)
Corresponding author
Marchant, Natalie L.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2012-05
Volume
33
Issue
5
Pages
1006.e25-1006.e36
ISSN
0197-4580 (ISSN-L)
OpenAlex
W1972661606
Cited by
127
References
86
Citations by year
2025: 1 · 2024: 6 · 2023: 13 · 2022: 6 · 2021: 7 · 2020: 11 · 2019: 10 · 2018: 10 · 2017: 3 · 2016: 15 · 2015: 11 · 2014: 15 · 2013: 13 · 2012: 5
FWCI
7.48
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • National Institutes of Health (AG012435, AG034570)
  • Alzheimer's Association (ZEN-08-87090)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Neurology › Cerebrovascular and genetic disorders
Keywords
cerebrovascular disease, amyloid-beta, cognitive aging, white matter hyperintensities, cerebral infarction, Pittsburgh compound B PET, executive function, episodic memory, normal aging, Alzheimer's disease
MeSH terms
Aged, Aged, 80 and over, Aging, Cerebrovascular Disorders, Cognition, Female, Humans, Male, Risk Factors, Cohort Studies, Amyloid beta-Peptides, Executive Function, Cognitive Dysfunction, Memory, Episodic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review